| | 
Part, Chapter, Paragraph
1 -, 1 | ii) produced through a 3-year process (from 15 November
2 -, 1 | and EU Agencies (Appendix 3); and (v) considered by
3 I, 2. 3 | 2.3. Migration~ ~The impact
4 I, 2. 5 | since the 80s. Figure 2.3 shows the significant differences
5 I, 2. 6 | secondary education (Table 2.3) and of total early school
6 I, 2. 6 | Figure 2.4).~ ~Table 2.3. Total population percentage
7 I, 2. 6 | by an average of almost 3 percentage points in the
8 I, 2. 7 | an estimated number of 3.3 billion people, will be
9 I, 2. 7 | an estimated number of 3.3 billion people, will be
10 I, 2. 9 | cover has decreased by 1.3 % per decade during the
11 I, 2. 9 | sea-level rise has increased to 3.1 mm/year in the past 15
12 I, 2. 10. 3 | 2.10.3. Information and communication
13 I, 2. 10. 4 | Event Study indicated that 9.3% of hospital stays incurred
14 I, 2. 10. 4 | administration errors (from 3.10% to 0.84%)11. Chelsea
15 I, 2. 10. 4 | the retail industry and 3-6% in the grocery industry –
16 I, 2. 11 | Circumpolar Health. 2007 Jun;66(3):188-98.~Medina c. et al. (
17 I, 3 | 3.~DEMOGRAPHY~ ~
18 I, 3. 1 | 3.1. Fertility and marriage
19 I, 3. 1 | States, the TFR was above 3.0: Cyprus, Ireland, Malta,
20 I, 3. 1 | even halved between 1975 (3.75) and 1994 (1.85), in
21 I, 3. 1 | Netherlands between 1964 (3.17) and 1977 (1.58), and
22 I, 3. 1 | in Portugal between 1968 (3.00) and 1993 (1.51). In
23 I, 3. 1 | fertility history (Figure 3.1)~ ~Figure 3.1. Total Period
24 I, 3. 1 | history (Figure 3.1)~ ~Figure 3.1. Total Period Fertility
25 I, 3. 2 | 3.2. Population growth and
26 I, 3. 2 | Bulgaria (-5%).~ ~Figure 3.2. Population size per Member
27 I, 3. 2 | the coming decades (Figure 3.2). Based on the EUROPOP
28 I, 3. 2 | the former EU15 (Figure 3.3).~ ~Figure 3.3. Natural
29 I, 3. 2 | the former EU15 (Figure 3.3).~ ~Figure 3.3. Natural
30 I, 3. 2 | EU15 (Figure 3.3).~ ~Figure 3.3. Natural increase rate
31 I, 3. 2 | Figure 3.3).~ ~Figure 3.3. Natural increase rate and
32 I, 3. 2 | Poland ( 5%), Italy (3%) and Netherlands (10%)
33 I, 3. 3 | 3.3. Population ageing~ ~The
34 I, 3. 3 | 3.3. Population ageing~ ~The
35 I, 3. 3 | expectancy changes.~ ~Figure 3.4. Age composition in EU27
36 I, 3. 3 | in EU27 in 2006~ ~Figure 3.5. Age composition in the
37 I, 3. 3 | end of that period (Figure 3.4 and Figure 3.5). Since
38 I, 3. 3 | period (Figure 3.4 and Figure 3.5). Since population pyramids
39 I, 3. 3 | trend in ageing. Figure 3.5.3 shows the percentage
40 I, 3. 3 | trend in ageing. Figure 3.5.3 shows the percentage of
41 I, 3. 3 | coming decade.~ ~Figure 3.6. Share of EU27 population
42 I, 3. 3 | increase, varying from 0.3% for the United Kingdom
43 I, 3. 3 | ratios will increase by 2.3% per year. The countries
44 I, 3. 4 | 3.4. References~ ~Beets G,
45 II, 4. 1 | Michel, 2004).~ ~Table 4.1.3 shows 10-year trends in
46 II, 4. 1 | within EU27.~ ~Table 4.1.3. Life expectancy at birth (
47 II, 4. 1 | increased in the EU27, by 3 years for men and by 2 years
48 II, 4. 1 | gap by 1 year (Table 4.1.3). Estimates shown in Table
49 II, 4. 1 | Estimates shown in Table 4.1.3 for LE only suggest a very
50 II, 4. 1 | birth in 2005 range from 65.3 years to 78.5 years (13.
51 II, 4. 2 | birth has increased by 2.3 years per decade for both
52 II, 4. 2 | 1 years in the 1980s and 3.0 years in the 1990s. For
53 II, 4. 2 | lower than in the 1970s (2.3 years), but similarly to
54 II, 4. 2 | EU15 average.~ ~Table 4.2.3 shows the Arriaga decomposition
55 II, 4. 2 | European Union.~ ~Table 4.2.3. Arriaga decomposition of
56 II, 4. 2 | causes 6, 7 and 8 in table 3) has contributed most to
57 II, 4. 2 | death, cancer (causes 2, 3, 4 and 5 in table 3), had
58 II, 4. 2 | causes 2, 3, 4 and 5 in table 3), had a smaller impact on
59 II, 4. 2 | cancers (cause 4 in table 3) had a negative impact on
60 II, 4. 2 | diseases (cause 1 in table 3) did not have a large effect
61 II, 4. 2 | diseases (cause 9 in table 3) declined in most countries.
62 II, 4. 2 | causes 10, 11 and 12 in table 3) has decreased in most countries.
63 II, 4. 2 | mortality (cause 13 in table 3) had a negative effect on
64 II, 4. 2 | death’ (cause 14 in table 3) across European countries.
65 II, 4. 2 | relationship (Figure 4.2.3). However, this is mainly
66 II, 4. 2 | countries.~ ~Figure 4.2.3. Relationship between the
67 II, 4. 3 | 4.3. References~ ~Anderson R,
68 II, 4. 3 | and Development Review 16(3): 403-432.~ ~Robine, J.-
69 II, 4. 3 | Journal of Public Health 13(3): 6-14.~ ~Robine, J.-M.,
70 II, 4. 3 | und Präventivmedizin 51(3): 153-161.~ ~World Health
71 II, 5. 1. 1 | within total causes of death; 3 years average (2001-2003),
72 II, 5. 1. 1 | within total causes of death; 3 years average (2001-2003),
73 II, 5. 1. 3 | 5.1.3. Therapeutic patient education~ ~
74 II, 5. 2. 2 | the average of the last 3 years available (2001-2003)
75 II, 5. 2. 2 | presented as average of the last 3 years available.~To make
76 II, 5. 2. 2 | the average of the last 3 years available in EU Member
77 II, 5. 2. 2 | rates derived from the last 3 years of surveillance. Annual
78 II, 5. 2. 2 | 5.2.2.3 Risk factors~CVD clinically
79 II, 5. 2. 3 | 5.2.3. Data description and analysis~ ~
80 II, 5. 2. 3 | 5.2.3.1. Ischemic heart disease~ ~
81 II, 5. 2. 3 | and reported in Table 5.2.3 (Allender et al, 2008).
82 II, 5. 2. 3 | patients with IHD.~ ~Table 5.2.3. Crude rates per 1 million
83 II, 5. 2. 3 | 5.2.3.2. Stroke~Data on morbidity
84 II, 5. 2. 3 | women aged 35-74 and 35-84 - 3 years average~ ~In men,
85 II, 5. 2. 3 | are shown in Figure 5.2.3; from 1994 to 2003 mortality
86 II, 5. 2. 3 | Eastern Europe.~ ~Figure 5.2.3. Age-standardized (standard
87 II, 5. 2. 3 | attack rates of the last 3 years of surveillance for
88 II, 5. 2. 3 | 100.000 mean of the last 3 years of the 10- year surveillance
89 II, 5. 2. 5 | diabetes mellitus see Section 3.1.5. Annex 1 is also relevant
90 II, 5. 2. 6 | intake to less than 1,5 g (3,8 g) per day, an increased
91 II, 5. 2. 7 | Group. N Engl J Med 344: 3-10.~Sans S, Kesteloot H,
92 II, 5. 2. 7 | World Health Stat Q 41(3-4):155–178.~Unal B, Critchley
93 II, 5. 3 | 5.3. Cancer~ ~
94 II, 5. 3. 1 | 5.3.1 Introduction~ ~Cancer
95 II, 5. 3. 1 | diagnosis (i.e. 1-year, 3-years, 5-years after diagnosis);~ ~
96 II, 5. 3. 1 | health relevance. Table 5.3.1 shows the burden of these
97 II, 5. 3. 1 | estimated in 2006.~ ~Table 5.3.1. Estimated incident cases
98 II, 5. 3. 2 | 5.3.2 Data sources~ ~
99 II, 5. 3. 2 | 5.3.2.1 Cancer Registration~ ~
100 II, 5. 3. 2 | 5.3.2.2 Data from European networks
101 II, 5. 3. 2 | org/content/vol18/suppl_3/index.dtl.~ ~ ~ ~
102 II, 5. 3. 3 | 5.3.3 Data presentation~ ~Cancer
103 II, 5. 3. 3 | 5.3.3 Data presentation~ ~Cancer
104 II, 5. 3. 4 | 5.3.3 Risk factors~ ~The majority
105 II, 5. 3. 4 | 5.3.3 Risk factors~ ~The majority
106 II, 5. 3. 5 | 5.3.4 Mortality and incidence
107 II, 5. 3. 5 | care performance. In 2006, 3,200,000 new cases and 1,
108 II, 5. 3. 5 | incidence rates (Figures 5.3.1) were estimated in Hungary
109 II, 5. 3. 5 | mortality rates (Figures 5.3.3) were estimated in Hungary
110 II, 5. 3. 5 | mortality rates (Figures 5.3.3) were estimated in Hungary
111 II, 5. 3. 5 | cases per 100,000, Figure 5.3.2a) and in Northern Europe
112 II, 5. 3. 5 | cases per 100,000, Figure 5.3.2b), while the highest mortality
113 II, 5. 3. 5 | deaths per 100,000, Figure 5.3.4a) and again in Northern
114 II, 5. 3. 5 | deaths per 100,000, Figure 5.3.4b).~Figures 5.3.2 show
115 II, 5. 3. 5 | Figure 5.3.4b).~Figures 5.3.2 show that incidence rates
116 II, 5. 3. 5 | the contrary, Figures 5.3.4 show that mortality is
117 II, 5. 3. 5 | constant for women.~ ~Figure 5.3.1a. All cancer (ICD9 140-
118 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.1b. All cancer (ICD9 140-
119 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.2a. Trends of all cancer (
120 II, 5. 3. 5 | by sex A) Men~Figure 5.3.2b. Trends of all cancer (
121 II, 5. 3. 5 | sex B) Women~ ~ ~Figure 5.3.3a. All cancer (ICD9 140-
122 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.3b. All cancer (ICD9 140-
123 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.4a. Trends of all cancer (
124 II, 5. 3. 5 | by sex A) Men~Figure 5.3.4b. Trends of all cancer (
125 II, 5. 3. 5 | incidence rates (Figures 5.3.5) were estimated in Macedonia
126 II, 5. 3. 5 | mortality rates (Figures 5.3.7) were estimated in Lithuania
127 II, 5. 3. 5 | men and women (Figures 5.3.5 and Figures 5.3.7). Stomach
128 II, 5. 3. 5 | Figures 5.3.5 and Figures 5.3.7). Stomach cancer incidence (
129 II, 5. 3. 5 | mortality trends (Figures 5.3.8) are decreasing both for
130 II, 5. 3. 5 | and mortality.~ ~Figure 5.3.5a. Stomach cancer (ICD9
131 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.5b. Stomach cancer (ICD9
132 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.6a. Trends of stomach cancer (
133 II, 5. 3. 5 | by sex A) Men~Figure 5.3.6b. Trends of stomach cancer (
134 II, 5. 3. 5 | sex B) Women~ ~Figure 5.3.7a. Stomach cancer (ICD9
135 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.7b. Stomach cancer (ICD9
136 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.8a. Trends of stomach cancer (
137 II, 5. 3. 5 | by sex A) Men~Figure 5.3.8b. Trends of stomach cancer (
138 II, 5. 3. 5 | et al, 2007). Figures 5.3.9 show that maximum incidence
139 II, 5. 3. 5 | men and women (Figures 5.3.10) (65 new cases in men
140 II, 5. 3. 5 | 000 in women). Figures 5.3.11 show that Hungary, Czech Republic
141 II, 5. 3. 5 | mainly for men (Figure 5.3.10a). Male mortality rates (
142 II, 5. 3. 5 | mortality rates (Figure 5.3.12a) are declining in Western
143 II, 5. 3. 5 | Southern Europe.~ ~Figure 5.3.9a. Colorectal cancer (ICD9
144 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.9b. Colorectal cancer (ICD9
145 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.10a. Trends of colorectal
146 II, 5. 3. 5 | by sex A) Men~Figure 5.3.10b. Trends of colorectal
147 II, 5. 3. 5 | sex B) Women~ ~Figure 5.3.11a. Colorectal cancer (
148 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.11b. Colorectal cancer (
149 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.12a. Trends of colorectal
150 II, 5. 3. 5 | by sex A) Men~Figure 5.3.12b. Trends of colorectal
151 II, 5. 3. 5 | rates are lower.~Figures 5.3.13a and 5.3.15a show that
152 II, 5. 3. 5 | lower.~Figures 5.3.13a and 5.3.15a show that Hungary had
153 II, 5. 3. 5 | levels of incidence (Figure 5.3.14a) and mortality (Figure
154 II, 5. 3. 5 | and mortality (Figure 5.3.16a) rates (in respect of
155 II, 5. 3. 5 | maximum incidence (Figure 5.3.14b) and mortality (Figure
156 II, 5. 3. 5 | and mortality (Figure 5.3.16b) rates for women (31
157 II, 5. 3. 5 | considered as shown in Figures 5.3.14a and 5.3.16a. In contrast,
158 II, 5. 3. 5 | in Figures 5.3.14a and 5.3.16a. In contrast, incidence
159 II, 5. 3. 5 | increasing for women (Figure 5.3.14b and 5.3.16b).~ ~Figure
160 II, 5. 3. 5 | women (Figure 5.3.14b and 5.3.16b).~ ~Figure 5.3.13a.
161 II, 5. 3. 5 | and 5.3.16b).~ ~Figure 5.3.13a. Lung cancer (ICD9 162)
162 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.13b. Lung cancer (ICD9 162)
163 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.14a. Trends of lung cancer (
164 II, 5. 3. 5 | by sex A) Men~Figure 5.3.14b. Trends of lung cancer (
165 II, 5. 3. 5 | sex B) Women~ ~Figure 5.3.15a. Lung cancer (ICD9 162)
166 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.15b. Lung cancer (ICD9 162)
167 II, 5. 3. 5 | 2006 B) Women~ ~Figure 5.3.16a. Trends of lung cancer (
168 II, 5. 3. 5 | by sex A) Men~Figure 5.3.16b. Trends of lung cancer (
169 II, 5. 3. 5 | implementation.~Figure 5.3.17 shows that the maximum
170 II, 5. 3. 5 | associated with GDP.~Figure 5.3.19 shows that in 2007 mortality
171 II, 5. 3. 5 | Mortality trends (Figure 5.3.20) are decreasing in Northern
172 II, 5. 3. 5 | Eastern Europe.~ ~Figure 5.3.17. Female breast cancer (
173 II, 5. 3. 5 | standard) in 2006~Figure 5.3.18. Trends of female breast
174 II, 5. 3. 5 | European standard)~Figure 5.3.19. Female breast cancer (
175 II, 5. 3. 5 | standard) in 2006~Figure 5.3.20. Trends of female breast
176 II, 5. 3. 5 | associated with GDP (Figure 5.3.21). This could be caused
177 II, 5. 3. 5 | Northern Europe (Figure 5.3.22 and Figure 5.3.24) where
178 II, 5. 3. 5 | Figure 5.3.22 and Figure 5.3.24) where there are well-developed
179 II, 5. 3. 5 | screening programs.~ ~Figure 5.3.21. Cervical cancer (ICD9
180 II, 5. 3. 5 | standard) in 2002~Figure 5.3.22. Trends of cervical cancer (
181 II, 5. 3. 5 | European standard)~Figure 5.3.23. Uterus cancer standardized
182 II, 5. 3. 5 | 44 in 1996-2001~Figure 5.3.24. Trends of uterus cancer
183 II, 5. 3. 5 | associated with GDP (Figure 5.3.25) possibly due to the
184 II, 5. 3. 5 | Southern Europe (Figure 5.3.26) reflects the PSA test
185 II, 5. 3. 5 | rates by years (Figure 5.3.28) are constant in Northern
186 II, 5. 3. 5 | Eastern Europe.~ ~Figure 5.3.25. Prostate cancer (ICD9
187 II, 5. 3. 5 | standard) in 2006~Figure 5.3.26. Trends of prostate cancer (
188 II, 5. 3. 5 | European standard)~Figure 5.3.27. Prostate cancer (ICD9
189 II, 5. 3. 5 | standard) in 2006~Figure 5.3.28. Trends of prostate cancer (
190 II, 5. 3. 6 | 5.3.5 Survival data discussion~ ~
191 II, 5. 3. 6 | 5.3.5.1 Childhood cancer survival~ ~
192 II, 5. 3. 6 | 5.3.5.2 Adult cancer survival~ ~
193 II, 5. 3. 6 | For this reason Figures 5.3.29 show 5-year relative
194 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.29a. All cancers (ICD9 140-
195 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.29b. All cancers (ICD9 140-
196 II, 5. 3. 6 | of prognosis (Figures 5.3.30). 5-year relative survival
197 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.30a. Stomach cancer (ICD9
198 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.30b. Stomach cancer (ICD9
199 II, 5. 3. 6 | relative survival (Figures 5.3.31) was over than 48% for
200 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.31a. Colorectal cancer (
201 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.31b. Colorectal cancer (
202 II, 5. 3. 6 | men and women (Figures 5.3.32). Estimates of 1-year
203 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.32a. Lung cancer (ICD9 162)
204 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.32b. Lung cancer (ICD9 162)
205 II, 5. 3. 6 | relative survival (Figure 5.3.33) exceeding 75% in most
206 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.33. Female breast cancer (
207 II, 5. 3. 6 | in Sweden (70%) (Figure 5.3.34) (Sant et al, 2003).
208 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.34. Cervical cancer (ICD9
209 II, 5. 3. 6 | diagnosis stood at 67% (Figure 5.3.35). 5-year relative survival
210 II, 5. 3. 6 | et al, 2003).~ ~Figure 5.3.35. Prostate cancer (ICD9
211 II, 5. 3. 7 | 5.3.6 Control tools and policies~ ~
212 II, 5. 3. 7 | 5.3.6.1 Primary prevention~ ~
213 II, 5. 3. 7 | 5.3.6.2 Early diagnosis (secondary
214 II, 5. 3. 7 | pre-cancer lesions (with 3 or 5 years of interval);
215 II, 5. 3. 7 | cancer screening (with 2 or 3 years of interval) and men
216 II, 5. 3. 7 | 5.3.6.3. Oncologic care and
217 II, 5. 3. 7 | 5.3.6.3. Oncologic care and practice~ ~
218 II, 5. 3. 7 | 5.3.6.4 Cancer Plans~ ~Definition
219 II, 5. 3. 7 | Member States (see Table 5.3.2) consider national cancer
220 II, 5. 3. 7 | cancer control.~ ~Table 5.3.2. Cancer national control
221 II, 5. 3. 7 | 5.3.6.5 Research collaboration~ ~
222 II, 5. 3. 8 | 5.3.7 Future developments~ ~
223 II, 5. 3. 9 | 5.3.8 References~ ~Berrino F,
224 II, 5. 3. 9 | Europe in 2006. Ann Oncol 18(3):581-592.~ ~Gatta G, Capocaccia
225 II, 5. 3. 9 | Summary. Ann Onc 18 (Suppl 3): iii2–iii7.~ ~Micheli A,
226 II, 5. 3. 9 | Eur J Public Health 13(3 Suppl):116-118.~ ~Parkin
227 II, 5. 4. 1 | projection of 380 millions (7.3%) forecast for 2025. According
228 II, 5. 4. 1 | increase of 1.0% in only 3 years. Very important differences
229 II, 5. 4. 2 | 5.4.2.3. Quality of care monitoring~ ~
230 II, 5. 4. 2 | presented in Tables 5.4.3 and 5.4.4.~ ~Table 5.4.3.
231 II, 5. 4. 2 | 3 and 5.4.4.~ ~Table 5.4.3. EUDIP core indicators and
232 II, 5. 4. 2 | months with LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of diabetic
233 II, 5. 4. 2 | months with triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~
234 II, 5. 4. 2 | received laser treatment<3 months after diagnosis of
235 II, 5. 4. 2 | Triglycerides level >2.3 mmol/l is an important indicator
236 II, 5. 4. 2 | total cholesterol above 2.3 mmol/l.~Microalbuminuria
237 II, 5. 4. 2 | had laser treatment within 3 months.~Control of serum
238 II, 5. 4. 3 | 5.4.3 Data description and analysis~ ~
239 II, 5. 4. 3 | years, corresponding to 3.2% annually. When pooled
240 II, 5. 4. 3 | rates of increase were 6.3% (4.1-8.5%) for children
241 II, 5. 4. 3 | children aged 0-4 years, 3.1% (1.5-4.8%) for 5-9 years,
242 II, 5. 4. 3 | 5-9 years, and 2.4% (1.0-3.8%) for 10-14 years (Green,
243 II, 5. 4. 3 | indicators varied between 3 (Belgium) and 632 (Scotland),
244 II, 5. 4. 3 | Triglycerides level >2.3 mmol/l. In EUCID databases
245 II, 5. 4. 4 | found between EUCID (median=3%) and IDF (median=8.7%)
246 II, 5. 4. 4 | striking, the range being 3-632, something that may
247 II, 5. 4. 6 | 5.4.6.3. Secondary prevention~Screening
248 II, 5. 4. 6 | reported in section 5.4.3, which indicate clearly
249 II, 5. 4. 6 | different policy sectors;~3. open a platform for involving
250 II, 5. 4. 8 | Diabet Med. 1995 Mar;12(3):271-6~Beck, P, Battlogg,
251 II, 5. 4. 8 | Int J Clin Pract 61(4):680-3~Jönsson B (2002), CODE-2
252 II, 5. 4. 8 | TRIGR). Pediatr Diabetes 8(3):117-37~Waug A (2007): Screening
253 II, 5. 5.Int | equivalent to a reduction of 3% to 4% of the total GDP9.~ ~
254 II, 5. 5.Int | people with depression are 2-3 times more likely to have
255 II, 5. 5.Int(15)| studies. World Psychiatry, 3:45–49.~
256 II, 5. 5.Int | bulimia it ranges from 0.3% to 7.3% in women and from
257 II, 5. 5.Int | it ranges from 0.3% to 7.3% in women and from 0.1%
258 II, 5. 5.Int | about 1% equivalent to some 3.7 million people. The disease
259 II, 5. 5.Int | in the EU varies between 3 and 6 per 1.000 inhabitants.
260 II, 5. 5. 1 | were gathered during 2001-3.~ ~· The Eurobarometer Surveys~ ~
261 II, 5. 5. 1 | 5.5.1.3. Data description and analysis~ ~
262 II, 5. 5. 1 | adults, collected during 2001-3. It represents a population
263 II, 5. 5. 1 | disorder.~ ~Table 5.5.1.3. Lifetime suicidal behaviour
264 II, 5. 5. 1 | Slovenia and Slovakia.~3) those with a higher prevalence
265 II, 5. 5. 1 | and Latvia.~ ~Figure 5.5.1.3. Odds ratio (with 95% confidence
266 II, 5. 5. 1 | rates (SMR) of the last 3 available years for suicide
267 II, 5. 5. 1 | Substance Abuse Families (2002-3).~o Mental health promotion
268 II, 5. 5. 1 | Disorders in Europe (2001-3) targeted people belonging
269 II, 5. 5. 1 | Psychiatry 68(suppl 2): 3-9.~ ~Berk M, Dodd S, Henry
270 II, 5. 5. 1 | Initiative. World Psychiatry 6(3):168-76.~ ~Kessler R, Nelson
271 II, 5. 5. 1 | disorders: results from 3 European studies. J Clin
272 II, 5. 5. 1 | 2005. Eur Psychiatry 22(3):146-52.~ ~S G (2005). The
273 II, 5. 5. 2 | is estimated to be 1.1-1.3%, and is constantly increasing.
274 II, 5. 5. 2 | 5.5.2.3. Data description and analysis~ ~
275 II, 5. 5. 2 | as follows:~ ~Table 5.5.2.3. The estimated number of
276 II, 5. 5. 2 | Framework Programme for a 3 year project entitled “European
277 II, 5. 5. 3 | 5.5.3. OTHER DISEASES~ ~
278 II, 5. 5. 3 | 5.5.3.1. Eating Disorders~ ~
279 II, 5. 5. 3 | 5.5.3.1.1. Introduction~ ~Eating
280 II, 5. 5. 3 | 5.5.3.1.2. Data sources~ ~ ~Qualitative
281 II, 5. 5. 3 | The overview in table 5.5.3.1.2.1 illustrates the limited
282 II, 5. 5. 3 | the project.~ ~Table 5.5.3.1.1 Overview of data availability
283 II, 5. 5. 3 | Turkey~ ~X~ ~ ~Table 5.5.3.1.2.1: Available data about
284 II, 5. 5. 3 | 5.5.3.1.3. Data description and
285 II, 5. 5. 3 | 5.5.3.1.3. Data description and analysis~ ~
286 II, 5. 5. 3 | average prevalence rate of 0.3% for young females in Western
287 II, 5. 5. 3 | 5.5.3.1.4. Risk factors and vulnerable
288 II, 5. 5. 3 | 5.5.3.1.5. Control tools and policies~ ~
289 II, 5. 5. 3 | 5.5.3.1.6. Future developments~ ~
290 II, 5. 5. 3 | 5.5.3.1.7. References~Alexander
291 II, 5. 5. 3 | 2001/2002 survey, chapter 3, 110-129. WHO Library Cataloguing
292 II, 5. 5. 3 | Health Report 2005 – Part 3 Child an adolescent health
293 II, 5. 5. 3 | 5.5.3.1.8 Acronyms~ ~DSMR-IV classification~
294 II, 5. 5. 3 | 5.5.3.2. Schizophrenia and disorders
295 II, 5. 5. 3 | 5.5.3.2.1. Introduction~ ~Schizophrenia (
296 II, 5. 5. 3 | 1000, period prevalence 3.3 per 1000, lifetime prevalence
297 II, 5. 5. 3 | 1000, period prevalence 3.3 per 1000, lifetime prevalence
298 II, 5. 5. 3 | schizophrenia should be 3 465 899 (htt ). Since relapses
299 II, 5. 5. 3 | 5.5.3.2.2. Data Sources~ ~There
300 II, 5. 5. 3 | 5.5.3.2.3. Data description and
301 II, 5. 5. 3 | 5.5.3.2.3. Data description and analysis~ ~
302 II, 5. 5. 3 | and Incidence~Figure 5.5.3.2.1. Estimated prevalence
303 II, 5. 5. 3 | prevalence of 4.6 per 1 000, 3.3 for period prevalence,
304 II, 5. 5. 3 | prevalence of 4.6 per 1 000, 3.3 for period prevalence, 4.
305 II, 5. 5. 3 | are missing in figure 5.5.3.3.2 due to lacking ICD-10
306 II, 5. 5. 3 | missing in figure 5.5.3.3.2 due to lacking ICD-10
307 II, 5. 5. 3 | documentation.~Figure 5.5.3.2.2. Inter-country comparison
308 II, 5. 5. 3 | ICD-10 codes: F20.~Figure 5.5.3.2.3. Admission rates trend
309 II, 5. 5. 3 | codes: F20.~Figure 5.5.3.2.3. Admission rates trend over
310 II, 5. 5. 3 | remains high.~Figure 5.5.3.2.4. Average length of stay -
311 II, 5. 5. 3 | populations (see Figure 5.5.3.3.2), the value reported
312 II, 5. 5. 3 | populations (see Figure 5.5.3.3.2), the value reported from
313 II, 5. 5. 3 | 11th and accounts for 2.3% of the years lived with
314 II, 5. 5. 3 | for 6.2% YLDs).~Table 5.5.3.2.1. DALYs due to schizophrenia~
315 II, 5. 5. 3 | of morbidity.~Table 5.5.3.2.2. Prevalence and adjusted
316 II, 5. 5. 3 | schizophrenia as compared to 2 – 3% in the general population.
317 II, 5. 5. 3 | Mini survey Finland 14.3%~NEMESIS Netherlands 53.
318 II, 5. 5. 3 | NEMESIS Netherlands 53.3%~ONS United Kingdom 15.0%~
319 II, 5. 5. 3 | et al, 2007) (Figure 5.5.3.3.5).~Figure 5.5.3.2.5:
320 II, 5. 5. 3 | al, 2007) (Figure 5.5.3.3.5).~Figure 5.5.3.2.5: Prescription
321 II, 5. 5. 3 | Figure 5.5.3.3.5).~Figure 5.5.3.2.5: Prescription of antipsychotics
322 II, 5. 5. 3 | in guidelines (Table 5.5.3.2.3).~Table 5.5.3.2.3. Psychosocial
323 II, 5. 5. 3 | guidelines (Table 5.5.3.2.3).~Table 5.5.3.2.3. Psychosocial
324 II, 5. 5. 3 | Table 5.5.3.2.3).~Table 5.5.3.2.3. Psychosocial interventions
325 II, 5. 5. 3 | 5.3.2.3).~Table 5.5.3.2.3. Psychosocial interventions
326 II, 5. 5. 3 | Collaboration, 2003) – see table 5.5.3.2.4.~Table 5.5.3.2.4. European
327 II, 5. 5. 3 | table 5.5.3.2.4.~Table 5.5.3.2.4. European practice guidelines
328 II, 5. 5. 3 | respective deficits.~Table 5.5.3.2.5. Mental health service
329 II, 5. 5. 3 | psychiatric nurses from 3 to 104, of psychologists
330 II, 5. 5. 3 | relatives) (Figure 5.5.3.3.6). Internalized stigma
331 II, 5. 5. 3 | relatives) (Figure 5.5.3.3.6). Internalized stigma
332 II, 5. 5. 3 | course of disease.~Figure 5.5.3.2.6. Experiences of stigma
333 II, 5. 5. 3 | outpatient care (see Table 5.5.3.3.6). Since psychotic disorders
334 II, 5. 5. 3 | outpatient care (see Table 5.5.3.3.6). Since psychotic disorders
335 II, 5. 5. 3 | Andlin-Sobocki (Figure 5.5.3.3.7), it can be assumed
336 II, 5. 5. 3 | Andlin-Sobocki (Figure 5.5.3.3.7), it can be assumed that
337 II, 5. 5. 3 | Lindström et al, 2007)~Table 5.5.3.2.6. Expenditures by kind
338 II, 5. 5. 3 | respect to F20-F29~Figure 5.5.3.2.7. Direct healthcare costs
339 II, 5. 5. 3 | Brain Council (Figure 5.5.3.3.8). Although not all countries
340 II, 5. 5. 3 | Brain Council (Figure 5.5.3.3.8). Although not all countries
341 II, 5. 5. 3 | into account.~Figure 5.5.3.2.8. Costs per case of schizophrenia
342 II, 5. 5. 3 | 5.5.3.2.4. Control tools and policies~ ~
343 II, 5. 5. 3 | 5.5.3.2.5. Future developments~ ~
344 II, 5. 5. 3 | 5.5.3.2.6. References~AGREE Collaboration (
345 II, 5. 5. 3 | Pract Epidemol Ment Health 3(1):23 [Epub ahead of print].~
346 II, 5. 5. 3 | Psychiatr Clin North Am 30(3):437-52.~Carney CP, Jones
347 II, 5. 5. 3 | Clinical Neuroscience Research 3(1-2):23-33.~Häfner H and
348 II, 5. 5. 3 | perspectives. World Psychiatry 5(3):130-8.~Häfner H, Maurer
349 II, 5. 5. 3 | Europe. World Psychiatry 4(3):161-7.~Knapp M, McDaid
350 II, 5. 5. 3 | 2002 to 2030. PLoS Med. 3(11):e442.~McGrath JJ (2006):
351 II, 5. 5. 3 | Arch Gen Psychiatry 62(3):247-53.~Pilling S, Bebbington
352 II, 5. 5. 3 | 5.5.3.2.7. Acronyms~ ~DALYs~Disability
353 II, 5. 5. 3 | 5.5.3.3. Autism Spectrum Disorder~ ~
354 II, 5. 5. 3 | 5.5.3.3. Autism Spectrum Disorder~ ~
355 II, 5. 5. 3 | 5.5.3.3.1. Introduction~ ~Autism
356 II, 5. 5. 3 | 5.5.3.3.1. Introduction~ ~Autism
357 II, 5. 5. 3 | until sometime between ages 3 and 7. They often have good
358 II, 5. 5. 3 | a condition occurring in 3 to 4 year olds characterized
359 II, 5. 5. 3 | 5.5.3.3.2. Data sources~ ~Autism
360 II, 5. 5. 3 | 5.5.3.3.2. Data sources~ ~Autism
361 II, 5. 5. 3 | 5.5.3.3.3. Data description and
362 II, 5. 5. 3 | 5.5.3.3.3. Data description and
363 II, 5. 5. 3 | 5.5.3.3.3. Data description and analysis~ ~
364 II, 5. 5. 3 | 5.5.3.3.4. Control tools and policies~ ~
365 II, 5. 5. 3 | 5.5.3.3.4. Control tools and policies~ ~
366 II, 5. 5. 3 | cost £2.7 billion (Euros 3.8 billion) annually, yet
367 II, 5. 5. 3 | 5.5.3.3.5. Future developments~ ~
368 II, 5. 5. 3 | 5.5.3.3.5. Future developments~ ~
369 II, 5. 5. 3 | 5.5.3.3.6. References~ ~Blaxill
370 II, 5. 5. 3 | 5.5.3.3.6. References~ ~Blaxill
371 II, 5. 5. 3 | 5.5.3.3.7. Acronyms~ ~ASD~Autism
372 II, 5. 5. 3 | 5.5.3.3.7. Acronyms~ ~ASD~Autism
373 II, 5. 5. 3 | 5.5.3.4. Epilepsy~ ~
374 II, 5. 5. 3 | 5.5.3.4.1. Introduction~ ~ ~Epilepsy
375 II, 5. 5. 3 | 5.5.3.4.2. Data sources~ ~The
376 II, 5. 5. 3 | 5.5.3.4.3. Data description and
377 II, 5. 5. 3 | 5.5.3.4.3. Data description and analysis~ ~
378 II, 5. 5. 3 | the continent (Table 5.5.3.4.1). The annual incidence
379 II, 5. 5. 3 | in the elderly (Table 5.5.3.4.2), even with significant
380 II, 5. 5. 3 | study design.~ ~Table 5.5.3.4.1. Incidence of epilepsy
381 II, 5. 5. 3 | epilepsy in Europe~ ~Table 5.5.3.4.2. Incidence (per 100,
382 II, 5. 5. 3 | generalized epilepsy in 6% (3.4 per 100,000 per year).
383 II, 5. 5. 3 | generally lower. The rate was 15.3 per 100,000 for localization-related
384 II, 5. 5. 3 | active epilepsy ranges from 3.2 to 7.8 per 1,000 (Table
385 II, 5. 5. 3 | 7.8 per 1,000 (Table 5.5.3.4.3). The prevalence is
386 II, 5. 5. 3 | per 1,000 (Table 5.5.3.4.3). The prevalence is lower
387 II, 5. 5. 3 | see above).~ ~Table 5.5.3.4.3. Prevalence of active
388 II, 5. 5. 3 | above).~ ~Table 5.5.3.4.3. Prevalence of active epilepsy
389 II, 5. 5. 3 | Children ~Prospective~560 ~3.6 ~Beilmann et al., 1999~
390 II, 5. 5. 3 | review and examination~396 ~5.3 ~Oun et al., 2003 (*)~Finland~
391 II, 5. 5. 3 | and examination~1233 ~6.3 ~Keranen et al., 1989 (*)~
392 II, 5. 5. 3 | and examination ~329/348 ~3.9/3.2~Eriksson and Koivikko,
393 II, 5. 5. 3 | examination ~329/348 ~3.9/3.2~Eriksson and Koivikko,
394 II, 5. 5. 3 | 199/235~ ~81/47~6.2/5.1~ ~3.9/5.2~ ~3.3/3.1~Granieri
395 II, 5. 5. 3 | 81/47~6.2/5.1~ ~3.9/5.2~ ~3.3/3.1~Granieri et al., 1989 (*) /
396 II, 5. 5. 3 | 47~6.2/5.1~ ~3.9/5.2~ ~3.3/3.1~Granieri et al., 1989 (*) /
397 II, 5. 5. 3 | 6.2/5.1~ ~3.9/5.2~ ~3.3/3.1~Granieri et al., 1989 (*) /
398 II, 5. 5. 3 | Children ~MR review~378 ~4.3 ~Endziniene et al., 1997~
399 II, 5. 5. 3 | review and examination~198 ~5.3 -~Waaler et al., 2000 (*)~
400 II, 5. 5. 3 | review and GP contacts~245 ~2.3 ~Krohn, 1961 (*) ~Poland~
401 II, 5. 5. 3 | domiciliary questionnaire~62 ~3.7Ø ~Ochoa Sangrador and
402 II, 5. 5. 3 | MR review? ~155/195 ~4.2/3.5~Sidenvall et al., 1996/
403 II, 5. 5. 3 | years ~MR review ~69 ~4.3 ~Tidman et al., 2003 (*)~+ =
404 II, 5. 5. 3 | generalized epilepsies (1.3 per 1,000) and undetermined
405 II, 5. 5. 3 | found to range from 1.6 to 9.3 in community-based studies
406 II, 5. 5. 3 | epilepsy ranges from 1.6 to 5.3 in children and adults (
407 II, 5. 5. 3 | Jallon, 2004) (Table 5.5.3.4.4). These data are confirmed
408 II, 5. 5. 3 | symptomatic seizures.~ ~Table 5.5.3.4.4. Community-based studies
409 II, 5. 5. 3 | Incident cohort~149~16.1~9.3~Loiseau et al., 1999~Iceland~
410 II, 5. 5. 3 | incident cohort~4001~1109.0~3.6~Nilsson et al, 1997~U.
411 II, 5. 5. 3 | MF~Incident cohort~149~58.3~2.6~Lhathoo et al., 2001~
412 II, 5. 5. 3 | not in remission had a 9.3 RR of death (95% CI 3.8-
413 II, 5. 5. 3 | 9.3 RR of death (95% CI 3.8-22.7) compared with patients
414 II, 5. 5. 3 | Donogue and Sander, 1997) to 3.5 per 1,000 in incidence
415 II, 5. 5. 3 | causes) was 4.9 (95% CI 2.7-8.3) vs. 7.9 (95% CI 2.6-18.
416 II, 5. 5. 3 | incidence of SUDEP was 2.5 vs. 6.3 per 1,000 (Nilsson et al,
417 II, 5. 5. 3 | Lindsen et al, 2001) and the 3 to 5-year remission rate
418 II, 5. 5. 3 | partial seizures)(Table 5.5.3.4.5). The issue of epilepsy
419 II, 5. 5. 3 | relationship.~ ~Table 5.5.3.4.5. National legislations
420 II, 5. 5. 3 | First seizure, idiopathic (3 months)~ Seizures not impairing
421 II, 5. 5. 3 | Seizures not impairing driving (3 months)~ Seizures during
422 II, 5. 5. 3 | normal~ diagnostic tests (3 months)~ Sporadic seizures (
423 II, 5. 5. 3 | No seizures in previous 3 years~Germany I 12 months
424 II, 5. 5. 3 | occasion-related seizures~ (3-6 months)~ First seizure,
425 II, 5. 5. 3 | First seizure, idiopathic (3-6 months)~ Treatment stop (
426 II, 5. 5. 3 | months)~ Treatment stop (ban 3 months)~ II 60 months (no
427 II, 5. 5. 3 | unprovoked, idiopathic seizure (3 months)~ Sporadic seizures (
428 II, 5. 5. 3 | single partial seizures (3 months)~ Treatment stop/
429 II, 5. 5. 3 | Treatment stop/change (ban 3 months)~ II 60 months (no
430 II, 5. 5. 3 | pattern established~ by 3 years~ II 120 months (no
431 II, 5. 5. 3 | 5.5.3.4.4. Control tools and policies~ ~
432 II, 5. 5. 3 | 5.5.3.4.5. Future developments~ ~
433 II, 5. 5. 3 | 5.5.3.4.6. References~ ~Anonymous (
434 II, 5. 5. 3 | revisited. Epileptic Disord 6:3-13.~Gaitatzis A, Carroll
435 II, 5. 5. 3 | childhood. Clin Dev Med 3:35-36.~Shackleton DP, Westerndorp
436 II, 5. 5. 3 | 5.5.3.4.7. Acronyms~ ~AED~Antiepileptic
437 II, 5. 5. 3 | 5.5.3.5 Multiple sclerosis~ ~
438 II, 5. 5. 3 | 5.5.3.5.1. Introduction~ ~Multiple
439 II, 5. 5. 3 | 5.5.3.5.2. Data sources~ ~The
440 II, 5. 5. 3 | Status Scale (EDSS) 0 to 3.5), moderate (4.0 to 6.5)
441 II, 5. 5. 3 | 5.5.3.5.3. Data description and
442 II, 5. 5. 3 | 5.5.3.5.3. Data description and analysis~ ~
443 II, 5. 5. 3 | summarised here. Tables 5.5.3.5.1-5.5.3.5.4 provide further
444 II, 5. 5. 3 | here. Tables 5.5.3.5.1-5.5.3.5.4 provide further details
445 II, 5. 5. 3 | where available.~ ~Table 5.5.3.5.1. Prevalence of Multiple
446 II, 5. 5. 3 | EUGLOREH Countries~ ~Table 5.5.3.5.2. Prevalence (per 100
447 II, 5. 5. 3 | Contries by gender~ ~Table 5.5.3.5.3. Prevalence (per 100
448 II, 5. 5. 3 | by gender~ ~Table 5.5.3.5.3. Prevalence (per 100 000)
449 II, 5. 5. 3 | best estimates)~ ~Table 5.5.3.5.4. Incidence (per 100
450 II, 5. 5. 3 | increased significantly from 3 to 6 per 100 000 per year
451 II, 5. 5. 3 | the prevalence increased 3.5-fold to 73 between 1973
452 II, 5. 5. 3 | male ratios between 1.1 and 3.4. Mean total prevalence
453 II, 5. 5. 3 | is reported in Table 5.5.3.5.5 and Figure 5.5.3.5.1.
454 II, 5. 5. 3 | 5.5.3.5.5 and Figure 5.5.3.5.1. RR-MS ranged from 24% (
455 II, 5. 5. 3 | Netherlands).~ ~Table 5.5.3.5.5. Proportion of Multiple
456 II, 5. 5. 3 | score is shown in Table 5.5.3.5.6 and Figure 5.5.3.5.2.
457 II, 5. 5. 3 | 5.5.3.5.6 and Figure 5.5.3.5.2. The estimated proportion
458 II, 5. 5. 3 | range for mild MS (EDSS 0-3.5) was 33% (UK) to 80% (
459 II, 5. 5. 3 | EDSS 7-9.5)~ ~Table 5.5.3.5.6. Proportion of Multiple
460 II, 5. 5. 3 | 2004a). However, rates up to 3.6 per 100 000 are reported
461 II, 5. 5. 3 | about 30 to 45.~ ~Table 5.5.3.5.7. Mortality (per 100
462 II, 5. 5. 3 | daily living.~ ~Figure 5.5.3.5.1. Distribution of total
463 II, 5. 5. 3 | 5.5.3.5.4. Risk factors~ ~MS is
464 II, 5. 5. 3 | 5.5.3.5.5. Control tools and policies~ ~
465 II, 5. 5. 3 | studies so that EDSS 0 to 3.5 refers to fully ambulatory
466 II, 5. 5. 3 | 5.5.3.5.6. Future developments~ ~
467 II, 5. 5. 3 | 5.5.3.5.7. References~ ~Bajenaru
468 II, 5. 5. 3 | 5.5.3.5.8. Acronyms~ ~ADL~Activities
469 II, 5. 5. 3 | 5.5.3.6. Parkinson’s disease~ ~ ~
470 II, 5. 5. 3 | 5.5.3.6.1. Introduction~ ~Parkinson’
471 II, 5. 5. 3 | 5.5.3.6.2. Data source~To identify
472 II, 5. 5. 3 | 5.5.3.6.3. Data description and
473 II, 5. 5. 3 | 5.5.3.6.3. Data description and analysis~ ~
474 II, 5. 5. 3 | European community (Figure 5.5.3.6.1. Estimated total number
475 II, 5. 5. 3 | disease in Europe~ ~Figure 5.5.3.6.1. Estimated total number
476 II, 5. 5. 3 | are shown in Table 5. 5. 3. 6. 1.~ ~Table 5.5.3.6.1.
477 II, 5. 5. 3 | 5. 3. 6. 1.~ ~Table 5.5.3.6.1. Incidence studies of
478 II, 5. 5. 3 | summarised in Table 5.5.3.6.2..(von Campenhausen et
479 II, 5. 5. 3 | et al, 2005).~ ~Table 5.5.3.6.2. Prevalence studies
480 II, 5. 5. 3 | a few studies (Table 5.5.3.6.3. Distribution of Parkinson’
481 II, 5. 5. 3 | few studies (Table 5.5.3.6.3. Distribution of Parkinson’
482 II, 5. 5. 3 | et al, 1986).~ ~Table 5.5.3.6.3. Distribution of Parkinson’
483 II, 5. 5. 3 | 1986).~ ~Table 5.5.3.6.3. Distribution of Parkinson’
484 II, 5. 5. 3 | including PD (Figure 5.5.3.6.2) (Andlin-Sobocki et
485 II, 5. 5. 3 | of €7,600.~ ~Figure 5.5.3.6.2. Cost per case in PD
486 II, 5. 5. 3 | five groups (Figure 5.5.3.6.3). In the early stages
487 II, 5. 5. 3 | five groups (Figure 5.5.3.6.3). In the early stages of
488 II, 5. 5. 3 | HY I) average cost are €3,400 per patient, whereas
489 II, 5. 5. 3 | HY IV).~ ~ ~Figure 5.5.3.6.3. Cost of Parkinson’s
490 II, 5. 5. 3 | IV).~ ~ ~Figure 5.5.3.6.3. Cost of Parkinson’s disease
491 II, 5. 5. 3 | 5.5.3.6.4. Risk factors~ ~The
492 II, 5. 5. 3 | 5.5.3.6.5. Control tools and policies~ ~
493 II, 5. 5. 3 | 5.5.3.6.6. Future developments~ ~
494 II, 5. 5. 3 | 2030 to results in 8.7 to 9.3 million (Dorsey et al, 2007).
495 II, 5. 5. 3 | 5.5.3.6.7. References~Aarsland
496 II, 5. 5. 3 | central Spain. Mov Disord 18(3):267-274.~Bergareche A,
497 II, 5. 5. 3 | Journal of neurology 251(3):340-345.~Bermejo F, Gabriel
498 II, 5. 5. 3 | of cases. Mov Disord 13(3):400-405.~Chrischilles EA,
499 II, 5. 5. 3 | s disease. Mov Disord 13(3):406-413.~Clarke CE, Zobkiw
500 II, 5. 5. 3 | An estimation based on a 3-month prospective analysis.
|
|
| |
